• レポートコード:D0JU09089 • 出版社/出版日:Transparency Market Research / 2020年2月10日 • レポート形態:英文、PDF、251ページ • 納品方法:Eメール • 産業分類:医療 |
Single User | ¥857,660 (USD5,795) | ▷ お問い合わせ |
Multi User | ¥1,301,660 (USD8,795) | ▷ お問い合わせ |
Corporate License | ¥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本調査レポートでは、キナーゼ阻害剤の世界市場について調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場動向、市場概要、種類別(非受容体型チロシンキナーゼ阻害剤、受容体型チロシンキナーゼ阻害剤、マルチキナーゼ阻害剤、セリン/トレオニンキナーゼ阻害剤、プロテインキナーゼC阻害剤、RHOキナーゼ阻害剤、その他)分析、用途別(腫瘍学、炎症性疾患、その他)分析、流通経路別(病院薬局、独立型薬局、オンライン薬局)分析、地域別分析、競争状況などの構成でお届けいたします。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場動向 ・市場概要 ・キナーゼ阻害剤の世界市場:種類別(非受容体型チロシンキナーゼ阻害剤、受容体型チロシンキナーゼ阻害剤、マルチキナーゼ阻害剤、セリン/トレオニンキナーゼ阻害剤、プロテインキナーゼC阻害剤、RHOキナーゼ阻害剤、その他) ・キナーゼ阻害剤の世界市場:用途別(腫瘍学、炎症性疾患、その他) ・キナーゼ阻害剤の世界市場:流通経路別(病院薬局、独立型薬局、オンライン薬局) ・キナーゼ阻害剤の世界市場:地域別 ・競争状況 |
Kinase Inhibitors Market – Scope of the Report
TMR’s report on the global kinase inhibitors market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators for the said market during the forecast period from 2019 to 2027. The report provides the overall market revenue of the global kinase inhibitors market for the period of 2017–2027, considering 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global kinase inhibitors market from 2019 to 2027.
The report has been prepared after an extensive research. Primary research involves bulk of research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Extensive secondary research involves referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global kinase inhibitors market.
Secondary research also includes Internet sources, statistical data from government agencies, websites, and trade associations. Analysts have employed a combination of top-down and bottom-up approaches to study various attributes of the global kinase inhibitors market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Moreover, the report sheds light on changing competitive dynamics in the global kinase inhibitors market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global kinase inhibitors market.
The report delves into the competitive landscape of the global kinase inhibitors market. Key players operating in the global kinase inhibitors market have been identified and each one of them has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global kinase inhibitors market that have been profiled in this report.
Key Questions Answered in Kinase Inhibitors Market Report
What is the sales/revenue generated by the kinase inhibitors market across all regions during the forecast period?
What are the opportunities in the global kinase inhibitors market?
What are the major drivers, restraints, opportunities, and threats in the global market?
Which region is set to expand at the fastest CAGR during the forecast period?
Which product segment is expected to generate the highest revenue globally in 2027? Which segment is projected expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?
Kinase Inhibitors Market – Research Objectives and Research Approach
The comprehensive report on the global kinase inhibitors market begins with an overview, followed by the scope and objectives of the study. Following this, the report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller sections. The report comprises an exhaustive collection of graphs and tables that have been appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global kinase inhibitors market in terms of type, application, distribution channel, and region. Key segments under each criteria have been studied at length, and the market share for each of them at the end of 2027 has been provided herein. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global kinase inhibitors market.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Kinase Inhibitors Market
4. Market Overview
4.1. Introduction & Overview
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Porter’s Five Forces Analysis
4.4. Global Kinase Inhibitors Market Analysis and Forecast, 2017–2027
5. Market Outlook
5.1. Pipeline Analysis
5.2. Brand Analysis
5.3. Recent Developments In Kinase Inhibitors Research
6. Global Kinase Inhibitors Market Analysis and Forecasts, by Type
6.1. Introduction & Definition
6.2. Global Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027
6.2.1. Non-receptor Tyrosine Kinase Inhibitors
6.2.1.1. Bruton’s Tyrosine Kinase (BTK) Inhibitors
6.2.1.2. BCR-ABL
6.2.1.3. Janus Kinase (JAK) Inhibitor
6.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)
6.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors
6.2.1.6. Others
6.2.2. Receptor Tyrosine Kinase Inhibitors
6.2.2.1. VEGFR
6.2.2.2. PDGFR
6.2.2.3. EGFR
6.2.2.4. ALK
6.2.2.5. HER2
6.2.2.6. Others
6.2.3. Multikinase inhibitors
6.2.4. Serine/Threonine Kinase Inhibitors
6.2.5. Protein Kinase C Inhibitors
6.2.6. RHO Kinase Inhibitors
6.2.7. Others
6.3. Global Kinase Inhibitors Market Attractiveness, by Type
7. Global Kinase Inhibitors Market Analysis and Forecasts, by Application
7.1. Introduction & Definition
7.2. Global Kinase Inhibitors Market Value (US$) Forecast, by Application, 2017–2027
7.2.1. Oncology
7.2.1.1. Lung Cancer
7.2.1.2. Renal cell cancer
7.2.1.3. Breast Cancer
7.2.1.4. Others
7.2.2. Inflammatory Diseases
7.2.3. Others
7.3. Global Kinase Inhibitors Market Attractiveness, by Application
8. Global Kinase Inhibitors Market Analysis and Forecasts, by Distribution Channel
8.1. Introduction & Definition
8.2. Global Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
8.2.1. Hospital Pharmacies
8.2.2. Independent Pharmacies
8.2.3. Online Pharmacies
8.3. Global Kinase Inhibitors Market Attractiveness, by Distribution Channel
9. Global Kinase Inhibitors Market Analysis and Forecasts, by Region
9.1. Key Findings
9.2. Global Kinase Inhibitors Market Value (US$ Mn) Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Global Kinase Inhibitors Market Attractiveness, by Region
10. North America Kinase Inhibitors Market Analysis and Forecast
10.1. Introduction
10.2. North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027
10.2.1. Non-receptor Tyrosine Kinase Inhibitors
10.2.1.1. Bruton’s Tyrosine Kinase (BTK) Inhibitors
10.2.1.2. BCR-ABL
10.2.1.3. Janus Kinase (JAK) Inhibitor
10.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)
10.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors
10.2.1.6. Others
10.2.2. Receptor Tyrosine Kinase Inhibitors
10.2.2.1. VEGFR
10.2.2.2. PDGFR
10.2.2.3. EGFR
10.2.2.4. ALK
10.2.2.5. HER2
10.2.2.6. Others
10.2.3. Multikinase inhibitors
10.2.4. Serine/Threonine Kinase Inhibitors
10.2.5. Protein Kinase C Inhibitors
10.2.6. RHO Kinase Inhibitors
10.2.7. Others
10.3. North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027
10.3.1. Oncology
10.3.1.1. Lung Cancer
10.3.1.2. Renal cell cancer
10.3.1.3. Breast Cancer
10.3.1.4. Others
10.3.2. Inflammatory Diseases
10.3.3. Others
10.4. North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
10.4.1. Hospital Pharmacies
10.4.2. Independent Pharmacies
10.4.3. Online Pharmacies
10.5. North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country, 2017–2027
10.5.1. U.S.
10.5.2. Canada
10.6. North America Kinase Inhibitors Market Attractiveness Analysis
10.6.1. By Type
10.6.2. By Application
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Kinase Inhibitors Market Analysis and Forecast
11.1. Introduction
11.2. Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027
11.2.1. Non-receptor Tyrosine Kinase Inhibitors
11.2.1.1. Bruton’s Tyrosine Kinase (BTK) Inhibitors
11.2.1.2. BCR-ABL
11.2.1.3. Janus Kinase (JAK) Inhibitor
11.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)
11.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors
11.2.1.6. Others
11.2.2. Receptor Tyrosine Kinase Inhibitors
11.2.2.1. VEGFR
11.2.2.2. PDGFR
11.2.2.3. EGFR
11.2.2.4. ALK
11.2.2.5. HER2
11.2.2.6. Others
11.2.3. Multikinase inhibitors
11.2.4. Serine/Threonine Kinase Inhibitors
11.2.5. Protein Kinase C Inhibitors
11.2.6. RHO Kinase Inhibitors
11.2.7. Others
11.3. Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027
11.3.1. Oncology
11.3.1.1. Lung Cancer
11.3.1.2. Renal cell cancer
11.3.1.3. Breast Cancer
11.3.1.4. Others
11.3.2. Inflammatory Diseases
11.3.3. Others
11.4. Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
11.4.1. Hospital Pharmacies
11.4.2. Independent Pharmacies
11.4.3. Online Pharmacies
11.5. Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Europe Kinase Inhibitors Market Attractiveness Analysis
11.6.1. By Type
11.6.2. By Application
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Kinase Inhibitors Market Analysis and Forecast
12.1. Introduction
12.2. Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027
12.2.1. Non-receptor Tyrosine Kinase Inhibitors
12.2.1.1. Bruton’s Tyrosine Kinase (BTK) Inhibitors
12.2.1.2. BCR-ABL
12.2.1.3. Janus Kinase (JAK) Inhibitor
12.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)
12.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors
12.2.1.6. Others
12.2.2. Receptor Tyrosine Kinase Inhibitors
12.2.2.1. VEGFR
12.2.2.2. PDGFR
12.2.2.3. EGFR
12.2.2.4. ALK
12.2.2.5. HER2
12.2.2.6. Others
12.2.3. Multikinase inhibitors
12.2.4. Serine/Threonine Kinase Inhibitors
12.2.5. Protein Kinase C Inhibitors
12.2.6. RHO Kinase Inhibitors
12.2.7. Others
12.3. Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027
12.3.1. Oncology
12.3.1.1. Lung Cancer
12.3.1.2. Renal cell cancer
12.3.1.3. Breast Cancer
12.3.1.4. Others
12.3.2. Inflammatory Diseases
12.3.3. Others
12.4. Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
12.4.1. Hospital Pharmacies
12.4.2. Independent Pharmacies
12.4.3. Online Pharmacies
12.5. Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Asia Pacific Kinase Inhibitors Market Attractiveness Analysis
12.6.1. By Type
12.6.2. By Application
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Kinase Inhibitors Market Analysis and Forecast
13.1. Introduction
13.2. Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027
13.2.1. Non-receptor Tyrosine Kinase Inhibitors
13.2.1.1. Bruton’s Tyrosine Kinase (BTK) Inhibitors
13.2.1.2. BCR-ABL
13.2.1.3. Janus Kinase (JAK) Inhibitor
13.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)
13.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors
13.2.1.6. Others
13.2.2. Receptor Tyrosine Kinase Inhibitors
13.2.2.1. VEGFR
13.2.2.2. PDGFR
13.2.2.3. EGFR
13.2.2.4. ALK
13.2.2.5. HER2
13.2.2.6. Others
13.2.3. Multikinase inhibitors
13.2.4. Serine/Threonine Kinase Inhibitors
13.2.5. Protein Kinase C Inhibitors
13.2.6. RHO Kinase Inhibitors
13.2.7. Others
13.3. Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027
13.3.1. Oncology
13.3.1.1. Lung Cancer
13.3.1.2. Renal cell cancer
13.3.1.3. Breast Cancer
13.3.1.4. Others
13.3.2. Inflammatory Diseases
13.3.3. Others
13.4. Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
13.4.1. Hospital Pharmacies
13.4.2. Independent Pharmacies
13.4.3. Online Pharmacies
13.5. Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Latin America Kinase Inhibitors Market Attractiveness Analysis
13.6.1. By Type
13.6.2. By Application
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Kinase Inhibitors Market Analysis and Forecast
14.1. Introduction
14.2. Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027
14.2.1. Non-receptor Tyrosine Kinase Inhibitors
14.2.1.1. Bruton’s Tyrosine Kinase (BTK) Inhibitors
14.2.1.2. BCR-ABL
14.2.1.3. Janus Kinase (JAK) Inhibitor
14.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)
14.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors
14.2.1.6. Others
14.2.2. Receptor Tyrosine Kinase Inhibitors
14.2.2.1. VEGFR
14.2.2.2. PDGFR
14.2.2.3. EGFR
14.2.2.4. ALK
14.2.2.5. HER2
14.2.2.6. Others
14.2.3. Multikinase inhibitors
14.2.4. Serine/Threonine Kinase Inhibitors
14.2.5. Protein Kinase C Inhibitors
14.2.6. RHO Kinase Inhibitors
14.2.7. Others
14.3. Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027
14.3.1. Oncology
14.3.1.1. Lung Cancer
14.3.1.2. Renal cell cancer
14.3.1.3. Breast Cancer
14.3.1.4. Others
14.3.2. Inflammatory Diseases
14.3.3. Others
14.4. Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
14.4.1. Hospital Pharmacies
14.4.2. Independent Pharmacies
14.4.3. Online Pharmacies
14.5. Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Israel
14.5.4. Rest of Middle East & Africa
14.6. Middle East & Africa Kinase Inhibitors Market Attractiveness Analysis
14.6.1. By Type
14.6.2. By Application
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Competition Matrix
15.2. Market Share Analysis, by Company (2018)
15.3. Company Profiles
15.3.1. Boehringer Ingelheim International GmbH
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Company Financials
15.3.1.3. Growth Strategies
15.3.1.4. SWOT Analysis
15.3.2. Novartis AG
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Company Financials
15.3.2.3. Growth Strategies
15.3.2.4. SWOT Analysis
15.3.3. AstraZeneca plc
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Company Financials
15.3.3.3. Growth Strategies
15.3.3.4. SWOT Analysis
15.3.4. Pfizer, Inc.
15.3.4.1. Company Overview (HQ, Business Segments)
15.3.4.2. Company Financials
15.3.4.3. Growth Strategies
15.3.4.4. SWOT Analysis
15.3.5. F. Hoffmann-La Roche Ltd
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Company Financials
15.3.5.3. Growth Strategies
15.3.5.4. SWOT Analysis
15.3.6. Bristol-Myers Squibb Company
15.3.6.1. Company Overview (HQ, Business Segments)
15.3.6.2. Company Financials
15.3.6.3. Growth Strategies
15.3.6.4. SWOT Analysis
15.3.7. Johnson & Johnson
15.3.7.1. Company Overview (HQ, Business Segments)
15.3.7.2. Company Financials
15.3.7.3. Growth Strategies
15.3.7.4. SWOT Analysis
15.3.8. Bayer AG
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Company Financials
15.3.8.3. Growth Strategies
15.3.8.4. SWOT Analysis
15.3.9. Eisai Co., Ltd.
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Company Financials
15.3.9.3. Growth Strategies
15.3.9.4. SWOT Analysis
List of TablesTable 01: Global BCR-ABL Tyrosine Kinase Inhibitors Market Revenue (US$ Mn) Forecast, by Key Brands, 2016-2026
Table 02: Global EGFR Tyrosine Kinase Inhibitors Market Revenue (US$ Mn) Forecast, by Key Brands, 2016-2026
Table 03: Global VEGFR Tyrosine Kinase Inhibitors Market Revenue (US$ Mn) Forecast, by Key Brands, 2016-2026
Table 04: Global Other Tyrosine Kinase Inhibitors Market Revenue (US$ Mn) Forecast, by Key Brands, 2016-2026
Table 05: Patent & Market Exclusivity Overview, by Molecule (1/4)
Table 06: Patent & Market Exclusivity Overview, by Molecule (2/4)
Table 07: Patent & Market Exclusivity Overview, by Molecule (3/4)
Table 08: Patent & Market Exclusivity Overview, by Molecule (4/4)
Table 09: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027
Table 10: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, by Non-receptor Tyrosine Kinase Inhibitors, 2017–2027
Table 11: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, by Receptor Tyrosine Kinase Inhibitors, 2017–2027
Table 12: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 13: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, by Oncology, 2017–2027
Table 14: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 15: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, by Region, 2017–2027
Table 16: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027
Table 17: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Non-receptor Tyrosine Kinase Inhibitors, 2017–2027
Table 18: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Receptor Tyrosine Kinase Inhibitors, 2017–2027
Table 19: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 20: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Oncology, 2017–2027
Table 21: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 22: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 23: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027
Table 24: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Non-receptor Tyrosine Kinase Inhibitors, 2017–2027
Table 25: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Receptor Tyrosine Kinase Inhibitors, 2017–2027
Table 26: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 27: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Oncology, 2017–2027
Table 28: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 29: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 30: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027
Table 31: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Non-receptor Tyrosine Kinase Inhibitors, 2017–2027
Table 32: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Receptor Tyrosine Kinase Inhibitors, 2017–2027
Table 33: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 34: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Oncology, 2017–2027
Table 35: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 36: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 37: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027
Table 38: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Non-receptor Tyrosine Kinase Inhibitors, 2017–2027
Table 39: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Receptor Tyrosine Kinase Inhibitors, 2017–2027
Table 40: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 41: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Oncology, 2017–2027
Table 42: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 43: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 44: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Type, 2017–2027
Table 45: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Non-receptor Tyrosine Kinase Inhibitors, 2017–2027
Table 46: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Receptor Tyrosine Kinase Inhibitors, 2017–2027
Table 47: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 48: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Oncology, 2017–2027
Table 49: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 50: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027